Similar articles

• Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

  Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Rigby MR, et al. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23. Lancet Diabetes Endocrinol. 2013. PMID: 24622414 Free PMC article. Clinical Trial.
• Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

  Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Rigby MR, et al. J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20. J Clin Invest. 2015. PMID: 26193635 Free PMC article. Clinical Trial.
• Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.

  Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG, Lowes MA. Chamian F, et al. J Transl Med. 2007 Jun 7;5:27. doi: 10.1186/1479-5876-5-27. J Transl Med. 2007. PMID: 17555598 Free PMC article. Clinical Trial.
• Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefacept.

  Weinberg JM, Tutrone WD. Weinberg JM, et al. Cutis. 2003 Jan;71(1):41-5. Cutis. 2003. PMID: 12553629 Review.
• Alefacept: an expert review concerning the treatment of psoriasis.

  Langley RG, Cherman AM, Gupta AK. Langley RG, et al. Expert Opin Pharmacother. 2005 Oct;6(13):2327-33. doi: 10.1517/14656566.6.13.2327. Expert Opin Pharmacother. 2005. PMID: 16218892 Review.